Trials / Terminated
TerminatedNCT02388152
Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease
Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if multiple immunizations with Lu AF20513 is tolerable and safe in patients with mild Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AF20513, low dose | |
| DRUG | Lu AF20513, medium dose | |
| DRUG | Lu AF20513, high dose | |
| DRUG | Lu AF20513, double high dose |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2019-07-04
- Completion
- 2019-07-04
- First posted
- 2015-03-13
- Last updated
- 2019-11-29
Locations
5 sites across 3 countries: Austria, Finland, Sweden
Source: ClinicalTrials.gov record NCT02388152. Inclusion in this directory is not an endorsement.